| Experienced management
Being in operations for almost two decades, the company has established its position in the lubricant additives segment both in the domestic as well as export markets leading to healthy stakeholder relationships. The promoter, Dr. Sunil Desai (PhD from University of Texas, at Austin, USA) has over three decades of experience in manufacturing and trading of specialty chemicals. He is ably supported by second generation, Mr. Rahul Sunil Desai (Chemical Engineer and MBA Finance from Rutgers University, USA) who looks after the day-to-day operations of the company. Moreover, the company is transitioning from trading to manufacturing of lubricant additives along with new business vertical of manufacturing of pharmaceutical products (such as effervescent tablets, general tablets, capsules and ointments) for which it has set up its own manufacturing unit at Sarigam, Vapi which commenced operations in FY26.
Moderate financial risk profile
The financial risk profile of the company is marked by moderate net worth of Rs. 55.22 Cr. as on March 31, 2026 (Prov.) as against Rs. 28.21 Cr. as on March 31, 2025, improved on account of accretion of profits to reserves and consideration of unsecured loans as a quasi-equity (amounting to Rs. 23.75 Cr. as on March 31, 2026) owing to covenant stipulated in the sanction letter and receipt of management undertaking. Further, the total debt of the company increased to Rs. 104.23 Cr. as on March 31, 2026 (Prov.) (Rs. 83.92 Cr. as on March 31, 2025) owing to higher utilization of working capital limits in FY26 post commencement of the new manufacturing unit. Therefore, the gearing (debt/equity) ratio of the company stood moderate at 1.89 times in FY26 (Prov.) (2.97 times in FY25). Further, the debt protection metrics stood moderate marked by interest coverage ratio of 2.42 times in FY26 (Prov.) (1.79 times in FY25) and debt service coverage ratio of 1.50 times in FY26 (Prov.) (1.08 times in FY25).
Going forward, the financial risk profile of the company is expected to improve on account of improving cash accruals and no major debt funded capex plans, which remains a key rating monitorable.
|
| Modest scale of operations
While the operating revenue of the company stood improved at Rs. 155.79 Cr. in FY26 (Prov.) (Rs. 142.81 Cr. in FY25) owing to the commencement of phased manufacturing unit (lubricant additive segment from April 2025 and pharmaceutical segment from December 2025), however, the commercialization and stabilization of these new segments leading to improvement in operating performance remains monitorable. Moreover, the manufacturing segment contributed ~82 percent of revenue in FY26 (~32 percent in FY25), while the trading segment’s share declined to ~18 percent from ~68 percent, reflecting a shift in the business profile from trading to manufacturing, resulting in an improvement in operating margins to ~16.01 percent in FY26 (Prov.) from 5.58 percent in FY25. Furthermore, over the years, with the improving domestic demand, the company has gradually increased their domestic presence from ~44 percent in FY23 to ~78 percent of revenue in FY26.
Going forward, timely stabilization of the operations leading to improvement in operating revenues and sustainability in the operating margins shall remain key rating monitorable.
Intensive working capital operations
The working capital operations of the company are intensive marked by gross current assets (GCA) of 243 days in FY26 (Prov.) as compared to 180 days in FY25, majorly driven by inventory and debtor levels. The inventory days of the company stood at 149 days in FY26 (Prov.) as compared to 72 days in FY25 owing to the inventory buildup for the manufacturing division. Moreover, the trade receivables stood at 95 days in FY26 (Prov.) (100 days in FY25) while the creditor days stood at 164 days in FY26 (Prov.) (189 days in FY25).
Susceptibility to fluctuations in raw-material prices, intense competition, and regulatory risks
The company remains exposed to volatility in key raw-material prices such as base oil (crude oil derivative), and specialty chemicals, which may affect margins given limited pricing flexibility. However, the company is able to pass on the fluctuations to its end customers to an extent. Further, the pharma and lubrication industry is highly competitive, with strong domestic and global players exerting pricing pressure. Moreover, the operations are subject to stringent regulatory and pharmacopeial compliance requirements across multiple export markets, making the business sensitive to evolving quality standards and audit-related risks. Additionally, over the past two years, the company has stopped hedging their foreign currency exposures. Thus, the company’s ability to improve its profitability margins amidst volatile input prices and forex fluctuations shall remain key rating monitorable.
|
